|
Sign In to gain access to subscriptions and/or personal tools.
|
Vascular Injury and Thrombotic Potential: A Note of Caution About Recombinant Factor VIIa
C. David Mazer, CD, MD, FRCPC
Departments of Anesthesia and Physiology, mazerd{at}smh.toronto.on.ca, Department of Surgery, University of Toronto
Howard Leong-Poi, MD, FRCPC
Department of Medicine, University of Toronto, Department of Surgery, University of Toronto
James Mahoney, MD, FRCSC
Department of Surgery, University of Toronto
David Latter, MD, FRCSC
Department of Surgery, University of Toronto
Bradley H. Strauss, MD, FRCPC
Department of Medicine, University of Toronto, Sunnybrook Health Sciences Centre, University of toronto, Keenan Research Centre, Li Ka Shing Knowledge Institute, and St Michael's Hospital, University of Toronto, Ontario, Canada
Jerome M. Teitel, MD, FRCPC
Department of Medicine, University of Toronto, Department of Surgery, University of Toronto
Postoperative hemorrhage following cardiac surgery increases morbidity, mortality, and costs. Several case reports have described the successful use of recombinant factor VIIa to decrease or stop bleeding in patients undergoing cardiac surgery. The mechanism of action of recombinant factor VIIa is thought to be increased site-specific thrombin generation by tissue factor—mediated activation of coagulation or from activated platelets. However, there have also been many reports of thrombotic complications after recombinant factor VIIa administration. Randomized clinical trials and further laboratory studies should help better clarify the efficacy, safety, cost-effectiveness, and optimal dosing of recombinant factor VIIa in the cardiac surgical setting.
Key Words: recombinant factor VIIa surgery cardiac surgery thrombosis complications
References
- Ferraris VA, Ferraris SP Limiting excessive postoperative blood transfusion after cardiac procedures. A review. Tex Heart Inst J. 1995;22:216-230.
- Spahn DR Eliminating blood transfusions: new aspects and perspectives. Anesthesiology. 2000;93:242-255.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Dacey LJ, Munoz JJ, Baribeau YR, et al. Reexploration for hemorrhage following coronary artery bypass grafting: incidence and risk factors. Arch Surg. 1998;133:442-447.[Abstract/Free Full Text]
- Despotis GJ, Filos KS, Zoys TN, Hogue CW Jr, Spitznagel E., Lappas DG Factors associated with excessive postoperative blood loss and hemostatic transfusion requirements: a multivariate analysis in cardiac surgical patients. Anesth Analg. 1996;82:13-21.[Abstract]
- Food and Drug Administration. Novoseven coagulation factor VIIa (recombinant). FDA Web site. 2003.
- Hedner U. Recombinant factor VIIa (Novoseven) as a hemostatic agent. Semin Hematol. 2001;38(4)(suppl 12): 43-47.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Kjalke M., Ezban M., Monroe DM, Hoffman M., Roberts HR, Hedner U. High-dose factor VIIa increases initial thrombin generation and mediates faster platelet activation in thrombocytopenia-like conditions in a cell-based model system. Br J Haematol. 2001;114:114-120.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Lindley CM, Sawyer WT, Macik BG, et al. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. Clin Pharmacol Ther. 1994;55:638-648.[Web of Science][Medline]
[Order article via Infotrieve]
- Hedner U. Dosing with recombinant factor VIIa based on current evidence. Semin Hematol. 2004;41(suppl 1): 35-39.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Hedner U., Glazer S., Pingel K., et al. Successful use of recombinant factor VIIa in patient with severe haemophilia A during synovectomy. Lancet. 1988;2:1193.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Naik VN, Mazer CD, Latter DA, Teitel JM, Hare GM Successful treatment using recombinant factor VIIa for severe bleeding post cardiopulmonary bypass. Can J Anaesth. 2003;50:599-502.[Web of Science][Medline]
[Order article via Infotrieve]
- Stratmann G., Russell IA, Merrick SH Use of recombinant factor VIIa as a rescue treatment for intractable bleeding following repeat aortic arch repair. Ann Thorac Surg. 2003;76:2094-2097.[Abstract/Free Full Text]
- Tanaka KA, Waly AA, Cooper WA, Levy JH Treatment of excessive bleeding in Jehovah's Witness patients after cardiac surgery with recombinant factor VIIa (NovoSeven). Anesthesiology. 2003;98:1513-1515.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- von Heymann C., Hotz H., Konertz W., Kox WJ, Spies C. Successful treatment of refractory bleeding with recombinant factor VIIa after redo coronary artery bypass graft surgery. J Cardiothorac Vasc Anesth. 2002;16:615-616.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Raivio P., Suojaranta-Ylinen R., Kuitunen, AH Recombinant factor VIIa in the treatment of postoperative hemorrhage after cardiac surgery. Ann Thorac Surg. 2005;80:66-71.[Abstract/Free Full Text]
- Karkouti K., Beattie WS, Wijeysundera DN, et al. Recombinant factor VIIa for intractable blood loss after cardiac surgery: a propensity score-matched case-control analysis. Transfusion. 2005;45:26-34.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Diprose P., Herbertson MJ, O'Shaughnessy D., Gill RS Activated recombinant factor VII after cardiopulmonary bypass reduces allogeneic transfusion in complex non-coronary cardiac surgery: randomized double-blind placebo-controlled pilot study. Br J Anaesth. 2005;95: 596-602.[Abstract/Free Full Text]
- Bishop CV, Renwick WE, Hogan C., Haeusler M., Tuckfield A., Tatoulis J. Recombinant activated factor VII: treating postoperative hemorrhage in cardiac surgery. Ann Thorac Surg. 2006;81:875-879.[Abstract/Free Full Text]
- von Heymann C., Redlich U., Jain U., et al. Recombinant activated factor VII for refractory bleeding after cardiac surgery—a retrospective analysis of safety and efficacy. Crit Care Med. 2005;33:2241-2246.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Gowers CJ Recombinant activated factor VIIa use in massive transfusion and coagulopathy unresponsive to conventional therapy. Anaesth Intensive Care. 2005;33: 196-200.[Web of Science][Medline]
[Order article via Infotrieve]
- STS Blood Conservation Guideline Task Force, Ferraris VA, Ferraris SP, Saha SP, et al. Perioperative blood transfusion and blood conservation in cardiac surgery: the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists clinical practice guideline. Ann Thorac Surg. 2007;83(suppl 5):S27-86.[Abstract/Free Full Text]
- Karkouti K., Beattie WS, Crowther MA, et al. The role of recombinant factor VIIa in on-pump cardiac surgery: proceedings of the Canadian Consensus Conference. Can J Anaesth. 2007;54:573-582.[Web of Science][Medline]
[Order article via Infotrieve]
- Erhardtsen E., Nony P., Dechavanne M., Ffrench P., Boissel JP, Hedner U. The effect of recombinant factor VIIa (NovoSeven) in healthy volunteers receiving acenocoumarol to an international normalized ratio above 2.0.Blood Coagul Fibrinolysis. 1998;9:741-748.[Web of Science][Medline]
[Order article via Infotrieve]
- Aledort LM rFVIIa—its thrombogenicity. Thromb Haemost. 2000;84:522-523.[Web of Science][Medline]
[Order article via Infotrieve]
- Roberts HR: Safety profile of recombinant factor VIIa. Semin Hematol. 2004;41(suppl 1):101-108.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Brown JL, Varma S., Morgan-Hughes NJ, Rocco G. Thrombosis related to emergency factor VIIa treatment. Anaesthesia. 2003;58:1245.[Web of Science][Medline]
[Order article via Infotrieve]
- O'Connell NM, Perry DJ, Hodgson AJ, O'Shaughnessy DF, Laffan MA, Smith OP Recombinant FVIIa in the management of uncontrolled hemorrhage. Transfusion. 2003;43:1711-1716.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Agarwal HS, Bennett JE, Churchwell KB, et al. Recombinant factor seven therapy for postoperative bleeding in neonatal and pediatric cardiac surgery. Ann Thorac Surg. 2007;84:161-168.[Abstract/Free Full Text]
- Mayer SA, Brun NC, Begtrup K., et al. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med. 2005;352:777-785.[Abstract/Free Full Text]
- Thomas GO, Dutton RP, Hemlock B., et al. Thromboembolic complications associated with factor VIIa administration. J Trauma. 2007;62:564-569.[Web of Science][Medline]
[Order article via Infotrieve]
- Food and Drug Administration. http://www.fda.gov/medwatch/SAFETY/2005/safety05.htm#NovoSeven.
- O'Connell KA, Wood JJ, Wise RP, Lozier JN, Braun MM Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA. 2006;295:293-298.[Abstract/Free Full Text]
- Mazer D., Leong-Poi H., Latter D., Strauss B., Teitel J. Effect of recombinant factor VIIa on vascular graft patency [abstract A852]. Anesthesiology. 2007;107.
- Charbonneau S., Girard F., Boudreault D., Ruel M., Blais N., Hardy JF Recombinant human activated factor VII is thrombogenic in a rabbit model of cyclic flow reduction and does not reduce intra-abdominal bleeding. Thromb Haemost. 2007;97:296-303.[Web of Science][Medline]
[Order article via Infotrieve]
Seminars in Cardiothoracic and Vascular Anesthesia, Vol. 11, No. 4,
261-264 (2007)
DOI: 10.1177/1089253207311357

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati Twitter What's this?
|
|